Kala Bio (KALA) Non Operating Income (2021 - 2026)
Kala Bio (KALA) posted Non Operating Income of $181000.0 for Q1 2026, down 98.34% sequentially from $10.9 million in Q4 2025, and down 89.49% YoY from $1.7 million in Q1 2025.
Kala Bio (KALA) Non Operating Income (2021 - 2026) Analysis & Trends
Kala Bio has reported Non Operating Income for 6 years, with the latest figure at $181000.0 in Q1 2026.
- Quarterly Non Operating Income fell 89.49% year-over-year to $181000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 161.43% YoY) and the FY2025 annual result came in at $12.2 million, up 392.76% from the prior year.
- Non Operating Income eased to $181000.0 in Q1 2026 per KALA's latest filing, from $10.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $43.6 million in Q3 2022 and troughed at -$2.8 million in Q1 2023.
- A 5-year average of $2.9 million and a median of $58000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income surged 2222.67% in 2022, then slumped 588.46% in 2025.
- Over 5 years, Non Operating Income stood at -$2.6 million in 2022, then surged by 138.27% to $992000.0 in 2023, then gained by 29.44% to $1.3 million in 2024, then jumped by 749.77% to $10.9 million in 2025, then slumped by 98.34% to $181000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $181000.0, $10.9 million, and -$325000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 181,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 181,000.00 |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | -325,000.00 |
| Jun 30, 2025 | -127,000.00 |
| Mar 31, 2025 | 1.72 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 26,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 992,000.00 |
| Sep 30, 2023 | 58,000.00 |
| Jun 30, 2023 | -814,000.00 |
| Mar 31, 2023 | -2.77 Mn |
| Dec 31, 2022 | -2.59 Mn |
| Sep 30, 2022 | 43.64 Mn |
| Jun 30, 2022 | -2.14 Mn |
| Mar 31, 2022 | -2.03 Mn |
| Dec 31, 2021 | -753,000.00 |
| Sep 30, 2021 | -2.06 Mn |